<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>327</serviceExecutionTime><Drug id="11633"><DrugName>GEM-240</DrugName><DrugSynonyms><Name><Value>GEM-240</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>oligonucleotide (RA), Hybridon/Searle</Value><Types><Type>Analogue</Type></Types></Name><Name><Value>oligonucleotide (HvGD), Hybridon/Searle</Value><Types><Type>Analogue</Type></Types></Name><Name><Value>oligonucleotide (MDM2), Hybridon/Searle</Value></Name><Name><Value>oligonucleotide (cancer), Hybridon/Searle</Value></Name><Name><Value>antisense oligonucleotides (MDM2), Hybridon</Value></Name><Name><Value>antisense oligonucleotides, Hybridon/Searle</Value></Name><Name><Value>oligonucleotide (autoimmune), Hybridon/Searle</Value><Types><Type>Analogue</Type></Types></Name><Name><Value>oligonucleotide (RA), Idera/Searle</Value></Name><Name><Value>oligonucleotide (HvGD), Idera/Searle</Value></Name><Name><Value>oligonucleotide (MDM2), Idera/Searle</Value></Name><Name><Value>oligonucleotide (cancer), Idera/Searle</Value></Name><Name><Value>antisense oligonucleotides (MDM2), Idera</Value></Name><Name><Value>antisense oligonucleotides, Idera/Searle</Value></Name><Name><Value>oligonucleotide (autoimmune), Idera/Searle</Value></Name></DrugSynonyms><CompanyOriginator id="17006">Idera Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="17006">Idera Pharmaceuticals Inc</Company><Company id="18362">GD Searle &amp; Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="11633" type="Drug"><TargetEntity id="326575" type="siDrug">GEM-240</TargetEntity></SourceEntity><SourceEntity id="17006" type="Company"><TargetEntity id="4295906738" type="organizationId">Idera Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="18362" type="Company"><TargetEntity id="5001166864" type="organizationId">GD Searle &amp; Co</TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"/><TargetEntity id="D001172" type="MeSH"/><TargetEntity id="-1391695545" type="omicsDisease"/><TargetEntity id="749" type="siCondition"/></SourceEntity><SourceEntity id="515" type="ciIndication"><TargetEntity id="10044439" type="MEDDRA"/><TargetEntity id="D006084" type="MeSH"/><TargetEntity id="1133" type="siCondition"/></SourceEntity><SourceEntity id="57" type="ciIndication"><TargetEntity id="10007649" type="MEDDRA"/><TargetEntity id="D002318" type="MeSH"/><TargetEntity id="-1500764314" type="omicsDisease"/><TargetEntity id="182" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="1588" type="Action"><TargetEntity id="1811" type="Mechanism">Drugs Targeting Apoptosis-Related Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="291">Rheumatoid arthritis</Indication><Indication id="515">Transplant rejection</Indication><Indication id="57">Cardiovascular disease</Indication><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="7294">Antisense oligonucleotide inhibitor</Action><Action id="1545">Anticancer</Action><Action id="1588">Apoptosis modulator</Action><Action id="2659">Cardioprotectant</Action></ActionsSecondary><Technologies><Technology id="569">Oligonucleotide antisense</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C</Code><Name>CARDIOVASCULAR SYSTEM</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-22T10:39:52.000Z</LastModificationDate><ChangeDateLast>2013-05-25T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Hybridon  (now &lt;ulink linkID="17006" linkType="Company"&gt;Idera Pharmaceuticals&lt;/ulink&gt;) was investigating GEM-240, an antisense oligonucleotide that targets MDM2 mRNA (an inhibitor of the tumor suppressor p53), for the potential treatment of cancer [&lt;ulink linkID="292121" linkType="reference"&gt;292121&lt;/ulink&gt;], [&lt;ulink linkID="455900" linkType="reference"&gt;455900&lt;/ulink&gt;]. In March 2000, Hybridon was seeking to outlicense codevelopment rights to the program [&lt;ulink linkID="358515" linkType="reference"&gt;358515&lt;/ulink&gt;]; by January 2001, progression toward IND was pending a commercial partner [&lt;ulink linkID="395711" linkType="reference"&gt;395711&lt;/ulink&gt;]. By October 2003, it appeared preclinical studies were ongoing [&lt;ulink linkID="507234" linkType="reference"&gt;507234&lt;/ulink&gt;]; however, by May 2005, the compound no longer appeared on the company's development pipeline [&lt;ulink linkID="619373" linkType="Reference"&gt;619373&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="18362" linkType="Company"&gt;Searle&lt;/ulink&gt; had been collaborating with Hybridon on this program since 1998, but did not extend the agreement when given the option to in March 2000 [&lt;ulink linkID="358515" linkType="reference"&gt;358515&lt;/ulink&gt;]. The companies had also been collaborating on the evaluation of antisense oligonucleotides for other indications, including rheumatoid arthritis (RA) and transplant rejection, since 1996 [&lt;ulink linkID="234855" linkType="reference"&gt;234855&lt;/ulink&gt;]; however, in 1998, the program was replaced with the MDM2 program [&lt;ulink linkID="292121" linkType="reference"&gt;292121&lt;/ulink&gt;], [&lt;ulink linkID="358515" linkType="reference"&gt;358515&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In February 2004, Hybridon published preclinical research demonstrating that the target of the nucleotide, MDM2, decreased the activity of p21 through direct physical interaction in cells and cell lysates. Direct regulation of p21 by MDM2 was shown to have an important role in tumor suppression, independent of p53 [&lt;ulink linkID="524534" linkType="reference"&gt;524534&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2003, preclinical data on GEM-240 were presented at the 94th AACR meeting, Washington, DC. In vitro, GEM-240 in combination with &lt;ulink linkID="11603" linkType="Drug"&gt;gefitinib&lt;/ulink&gt; (qv) synergistically inhibit hormone-refractory cancer cell growth. This inhibition was accompanied by inhibition of Mdm2, Akt and MAPK expression, reduced phosphorylation of Rb, and increased p53 expression. A potent cooperative antitumor effect was also observed in vivo in nude mice with hormone-refractory PC3 xenografts [&lt;ulink linkID="497910" linkType="reference"&gt;497910&lt;/ulink&gt;]. Additional data were published in October 2003. In three human prostate cancer cell lines (LNCaP with wild-type p53, DU145 with mutated p53, and PC3 with no p53), GEM-240 caused a concentration-dependent increase in apoptosis and inhibition of cell proliferation in vitro. Additionally, Mdm2 levels were significantly downregulated in Mdm2 antisense treated cells. The antisense activity was also observed using tumor xenografts of LNCaP and PC3 in mice [&lt;ulink linkID="507234" linkType="reference"&gt;507234&lt;/ulink&gt;], [&lt;ulink linkID="507243" linkType="reference"&gt;507243&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2003, Hybridon published data from a study designed to investigate the role of GEM-240 in human prostate cancer. The study also evaluated GEM-240 as a therapeutic agent, both when used alone and when used in combination with cancer chemotherapeutics. GEM-240 specifically inhibited MDM2 expression in a dose-dependent manner in the two prostate cancer cell lines (PC3 and DU145) studied, regardless of p53 status. Moreover, in individual tests of GEM-240 with each of the conventional cancer chemotherapeutic agents 10-hydroxycamptothecin, adriamycin, 5-fluorouracil, and paclitaxel, in vitro synergistic or additive effects on p53 activation were observed in cells with wild type, but not mutant, p53. In addition, in a dose-dependent manner, MDM2 inhibition resulted in the induction of p21 and apoptosis. Finally, the GEM-240 inhibited tumor growth in nude mice with human prostate cancer xenografts and increased the therapeutic effects of several anticancer agents [&lt;ulink linkID="479584" linkType="reference"&gt;479584&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2001, a preclinical study of GEM-240 with &lt;ulink linkID="2871" linkType="Drug"&gt;irinotecan&lt;/ulink&gt; was presented at the 92nd AACR meeting, New Orleans, LA. Significant improvements in therapeutic effectiveness including regression of tumors were observed in various nude mouse models of human cancers including colon, prostate, breast and leukemia when oligonucleotides and &lt;ulink linkID="2871" linkType="Drug"&gt;irinotecan&lt;/ulink&gt; were combined. Pharmacokinetic analysis revealed that pre-treatment with oligonucleotides increased the levels of the active metabolite of &lt;ulink linkID="2871" linkType="Drug"&gt;irinotecan&lt;/ulink&gt;, SN-38, in tumor tissues [&lt;ulink linkID="405545" linkType="reference"&gt;405545&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;A study presented in March 2000 demonstrated that inhibiting MDM2 oncogene expression could be used as a novel approach to cancer therapy. The overall objective of the study was to investigate the function of the MDM2 oncogene in tumor growth and the potential value of it as a drug target for cancer therapy. Significant in vitro antitumor activity of the antisense oligos was found in various human cancer cell lines, including LS174T (colon carcinoma), MCF-7 (breast cancer), A549 (lung cancer) and LNCap (prostate cancer). The in vitro antitumor activity was associated with repression of MDM2 expression, activation of p53, and increase in p53 function. Following ip administration of anti-MDM2 antisense oligos, in vivo antitumor activity was observed in nude mice bearing A549 and LS174T xenografts in a dose-dependent manner. In vivo, synergistic therapeutic effects of MDM2 antisense oligos and the anticancer agents adriamycin and 10-hydroxycamptothecin were also observed [&lt;ulink linkID="364032" linkType="reference"&gt;364032&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In January 1996, &lt;ulink linkID="18362" linkType="Company"&gt;Searle&lt;/ulink&gt; and Hybridon signed a letter of intent on an R&amp;amp;D and licensing collaboration to develop antisense compounds directed at up to eight molecular targets associated with immunomodulation, including RA and transplant rejection. &lt;ulink linkID="18362" linkType="Company"&gt;Searle&lt;/ulink&gt; was to fund the R&amp;amp;D of a lead compound, and had the option to expand the collaboration [&lt;ulink linkID="196858" linkType="reference"&gt;196858&lt;/ulink&gt;], [&lt;ulink linkID="234855" linkType="reference"&gt;234855&lt;/ulink&gt;]. In April 1998, the collaboration was extended to develop antisense compounds targeting the MDM2 oncogene for the potential treatment of various cancers. Under the amended agreement, &lt;ulink linkID="18362" linkType="Company"&gt;Searle&lt;/ulink&gt; was to be able to designate additional molecular targets in the fields of oncology and immunomodulation as well as in cardiovascular disease [&lt;ulink linkID="292121" linkType="reference"&gt;292121&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 1999, Hybridon obtained a non-exclusive license to patent rights relating to antisense compounds which inhibit MDM2 expression, methods for identifying such compounds and for their use in the treatment of cancer from &lt;ulink linkID="24859" linkType="Company"&gt;Genzyme Molecular Oncology&lt;/ulink&gt; [&lt;ulink linkID="341654" linkType="reference"&gt;341654&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17006">Idera Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="515">Transplant rejection</Indication><StatusDate>1998-04-01T00:00:00.000Z</StatusDate><Source id="358515" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18362">GD Searle &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2000-03-08T00:00:00.000Z</StatusDate><Source id="358515" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18362">GD Searle &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2000-03-08T00:00:00.000Z</StatusDate><Source id="358515" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17006">Idera Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="57">Cardiovascular disease</Indication><StatusDate>1998-04-01T00:00:00.000Z</StatusDate><Source id="358515" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17006">Idera Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>1998-04-01T00:00:00.000Z</StatusDate><Source id="358515" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18362">GD Searle &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="57">Cardiovascular disease</Indication><StatusDate>2000-03-08T00:00:00.000Z</StatusDate><Source id="358515" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18362">GD Searle &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="515">Transplant rejection</Indication><StatusDate>2000-03-08T00:00:00.000Z</StatusDate><Source id="358515" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17006">Idera Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2005-05-02T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17006">Idera Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate>1998-11-23T00:00:00.000Z</StatusDate><Source id="305950" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17006">Idera Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate>1996-02-01T10:18:45.000Z</StatusDate><Source id="196858" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17006">Idera Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>1996-02-01T10:18:45.000Z</StatusDate><Source id="196858" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18362">GD Searle &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate>1998-11-23T00:00:00.000Z</StatusDate><Source id="305950" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18362">GD Searle &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>1998-11-23T00:00:00.000Z</StatusDate><Source id="305950" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18362">GD Searle &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate>1996-02-01T00:00:00.000Z</StatusDate><Source id="196858" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18362">GD Searle &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>1996-02-01T00:00:00.000Z</StatusDate><Source id="196858" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17006">Idera Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>1998-11-23T00:00:00.000Z</StatusDate><Source id="305950" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17006">Idera Pharmaceuticals Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="12">Patent - Non-Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="115240" title="Searle and Hybridon to codevelop antisense compounds against targets in RA, transplant rejection and cancer    "/><Deal id="115245" title="Hybridon to develop antisense anticancer compounds based on Genzyme Molecular's IP  "/></Deals><PatentFamilies><PatentFamily id="1113821" number="WO-09320238" title="Amplification of human mdm2 gene in human tumors."/><PatentFamily id="1352550" number="WO-09402498" title="Hybrid oligonucleotide phosphorothioates."/><PatentFamily id="2348900" number="WO-09706253" title="Method Of Modulating Gene Expression With Reduced Immunostimulatory Response"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="2">Drug Target</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mirati Therapeutics Inc" id="1085701"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Idera Pharmaceuticals Inc" id="17006"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ionis Pharmaceuticals Inc" id="17269"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Carrus Capital Corp" id="18210"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johns Hopkins University" id="20596"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Worcester Foundation for Experimental Biology" id="20946"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Silence Therapeutics plc" id="22356"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pharmascience Inc" id="24846"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>